{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:29:31Z","timestamp":1794356971373,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:00:00Z","timestamp":1794355200000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1153049"],"award-info":[{"award-number":["1153049"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023812","name":"St Vincent's Curran Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023812","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Besins Healthcare"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Progesterone can inhibit tumoural proliferation in oestrogen receptor positive (ER+) breast cancer. The WinPro trial (Australian New Zealand Trials Clinical Trials Registry number: ACTRN12618000928213, date of registration 01\/06\/2018) was a randomised, multi-centre, phase 2, window-of-opportunity trial evaluating micronised progesterone (MP) in post-menopausal women with early-stage, ER+, progesterone receptor (PR) positive, HER2- breast cancer. Patients were randomised to letrozole, letrozole and MP, or tamoxifen and MP for 14 days preoperatively. The primary endpoint was the percent proportional reduction in Ki67 (\u2018Ki67 suppression\u2019) between the two letrozole groups in the per protocol population. From February 2018 to June 2024, 244 patients were enrolled. 189 patients completed per protocol: letrozole (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200966, 34.9%), letrozole + MP (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200964, 33.9%), and tamoxifen + MP (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200959, 31.2%). There was no difference in Ki67 suppression between letrozole (88.2%) versus letrozole + MP (89.2%) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.39). Ki67 suppression appeared lower with tamoxifen + MP (61.5%). Hot flushes appeared less frequent with letrozole + MP (13.3%) versus letrozole (22.4%) or tamoxifen + MP (20.5%).\n                  <\/jats:p>","DOI":"10.1038\/s41523-026-01008-w","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:53:56Z","timestamp":1784595236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The WinPro trial: window-of-opportunity study of endocrine therapy with micronised progesterone in ER-positive breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Lucy","family":"Haggstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davendra","family":"Segara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma-Kate","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda. E.","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanusha","family":"Sabanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aura","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey J.","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Swarbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Bruce","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"1008_CR1","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","DOI":"10.1038\/nature11412"},{"key":"1008_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836\u20131846 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1200\/JCO.2025.43.16_suppl.523","volume":"43","author":"J Wei","year":"2025","unstructured":"Wei, J. et al. Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients. J. Clin. Oncol. 43, 523\u2013523 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1008_CR4","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1158\/1078-0432.CCR-20-3974","volume":"27","author":"LJ Collin","year":"2021","unstructured":"Collin, L. J. et al. Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women. Clin. Cancer Res. 27, 1421\u20131428 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1008_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M. & Vernon, S. W. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res. Treat. 134, 459\u2013478 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"1008_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdn646","volume":"20","author":"V Ziller","year":"2009","unstructured":"Ziller, V. et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann. Oncol. 20, 431\u2013436 (2009).","journal-title":"Ann. Oncol."},{"key":"1008_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith, I. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 21, 1443\u20131454 (2020).","journal-title":"Lancet Oncol."},{"key":"1008_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed, H. et al. Progesterone receptor modulates ER\u03b1 action in breast cancer. Nature 523, 313\u2013317 (2015).","journal-title":"Nature"},{"key":"1008_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1994.12.8.1630","volume":"12","author":"HB Muss","year":"1994","unstructured":"Muss, H. B. et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J. Clin. Oncol. 12, 1630\u20131638 (1994).","journal-title":"J. Clin. Oncol."},{"key":"1008_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00000421-198204000-00062","volume":"5","author":"JN Ingle","year":"1982","unstructured":"Ingle, J. N. et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am. J. Clin. Oncol. 5, 155\u2013160 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"1008_CR11","doi-asserted-by":"publisher","unstructured":"Burrell, R. A. et al. Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-025-01087-x (2026).","DOI":"10.1038\/s43018-025-01087-x"},{"key":"1008_CR12","unstructured":"United States Food and Drug Administration. Drug Approval Package: Prometrium (Progesterone) Capsules, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/020843_s000_PrometriumTOC.cfm (2005)."},{"key":"1008_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0015-0282(99)00272-1","volume":"72","author":"LA Fitzpatrick","year":"1999","unstructured":"Fitzpatrick, L. A. & Good, A. Micronized progesterone: clinical indications and comparison with current treatments. Fertil. Steril. 72, 389\u2013397 (1999).","journal-title":"Fertil. Steril."},{"key":"1008_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jama.1996.03530290040035","volume":"275","author":"HL Judd","year":"1996","unstructured":"Judd, H. L. et al. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial. JAMA 275, 370\u2013375 (1996).","journal-title":"JAMA"},{"key":"1008_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3109\/09513590.2010.487613","volume":"27","author":"JL Cuadros","year":"2011","unstructured":"Cuadros, J. L. et al. Metabolic and hormonal parameters in post-menopausal women 10 years after transdermal oestradiol treatment, alone or combined to micronized oral progesterone. Gynecol. Endocrinol. 27, 156\u2013162 (2011).","journal-title":"Gynecol. Endocrinol."},{"key":"1008_CR16","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1016\/j.fertnstert.2010.07.733","volume":"94","author":"P Auerbach","year":"2010","unstructured":"Auerbach, P., Zipfel, L., Yang, H. M., Allgood, A. & Guo, C. Y. Evaluation of safety and efficacy of micronized progesterone in induction of secretory conversion of endometrium and withdrawal bleeding in women with secondary amenorrhea. Fertil. Steril. 94, S188\u2013S189 (2010).","journal-title":"Fertil. Steril."},{"key":"1008_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/gme.0b013e318247f07a","volume":"19","author":"CL Hitchcock","year":"2012","unstructured":"Hitchcock, C. L. & Prior, J. C. Oral micronized progesterone for vasomotor symptoms-a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 19, 886\u2013893 (2012).","journal-title":"Menopause"},{"key":"1008_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.breast.2016.11.016","volume":"31","author":"AL Cohen","year":"2017","unstructured":"Cohen, A. L. et al. POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast 31, 219\u2013223 (2017).","journal-title":"Breast"},{"key":"1008_CR19","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.1016\/j.annonc.2025.08.723","volume":"36","author":"A Llombart Cussac","year":"2025","unstructured":"Llombart Cussac, A. et al. 294MO Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)\/human epidermal growth factor receptor 2-negative (HER2-) and Ki67 \u226510% early breast cancer (EBC): The EMPRESS study. Ann. Oncol. 36, S323 (2025).","journal-title":"Ann. Oncol."},{"key":"1008_CR20","doi-asserted-by":"publisher","first-page":"951s","DOI":"10.1158\/1078-0432.951s.11.2","volume":"11","author":"M Dowsett","year":"2005","unstructured":"Dowsett, M. et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin. Cancer Res. 11, 951s\u2013958s (2005).","journal-title":"Clin. Cancer Res."},{"key":"1008_CR21","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/jama.2010.1500","volume":"304","author":"RT Chlebowski","year":"2010","unstructured":"Chlebowski, R. T. et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304, 1684\u20131692 (2010).","journal-title":"JAMA"},{"key":"1008_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/PPO.0000000000000602","volume":"28","author":"AZ Bluming","year":"2022","unstructured":"Bluming, A. Z. Introduction: estrogen reconsidered: exploring the evidence for estrogen\u2019s benefits and risks. Cancer J. 28, 157\u2013162 (2022).","journal-title":"Cancer J."},{"key":"1008_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13697137.2020.1851183","volume":"24","author":"RD Langer","year":"2021","unstructured":"Langer, R. D., Hodis, H. N., Lobo, R. A. & Allison, M. A. Hormone replacement therapy - where are we now? Climacteric 24, 3\u201310 (2021).","journal-title":"Climacteric"},{"key":"1008_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/13697137.2022.2035711","volume":"25","author":"DA Tan","year":"2022","unstructured":"Tan, D. A. & Dayu, A. R. B. Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. Climacteric 25, 362\u2013368 (2022).","journal-title":"Climacteric"},{"key":"1008_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/JCO.1999.17.1.64","volume":"17","author":"J Abrams","year":"1999","unstructured":"Abrams, J. et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J. Clin. Oncol. 17, 64\u201373 (1999).","journal-title":"J. Clin. Oncol."},{"key":"1008_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJM199408113310602","volume":"331","author":"CL Loprinzi","year":"1994","unstructured":"Loprinzi, C. L. et al. Megestrol acetate for the prevention of hot flashes. N. Engl. J. Med. 331, 347\u2013352 (1994).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR27","doi-asserted-by":"publisher","first-page":"T49","DOI":"10.1530\/JME-20-0104","volume":"65","author":"KB Horwitz","year":"2020","unstructured":"Horwitz, K. B. & Sartorius, C. A. 90 years of progesterone: progesterone and progesterone receptors in breast cancer: past, present, future. J. Mol. Endocrinol. 65, T49\u2013T63 (2020).","journal-title":"J. Mol. Endocrinol."},{"key":"1008_CR28","doi-asserted-by":"publisher","first-page":"182ra155","DOI":"10.1126\/scitranslmed.3005654","volume":"5","author":"T Tanos","year":"2013","unstructured":"Tanos, T. et al. Progesterone\/RANKL is a major regulatory axis in the human breast. Sci. Transl. Med. 5, 182ra155\u2013182ra155 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1008_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mce.2011.09.019","volume":"357","author":"NL Moore","year":"2012","unstructured":"Moore, N. L., Hickey, T. E., Butler, L. M. & Tilley, W. D. Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Mol. Cell Endocrinol. 357, 60\u201370 (2012).","journal-title":"Mol. Cell Endocrinol."},{"key":"1008_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","volume":"27","author":"TE Hickey","year":"2021","unstructured":"Hickey, T. E. et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat. Med. 27, 310\u2013320 (2021).","journal-title":"Nat. Med."},{"key":"1008_CR31","doi-asserted-by":"publisher","unstructured":"Manivannan, M. et al. Activated glucocorticoid receptor is an estrogen receptor silencer in ER+ metastatic breast cancer. EMBO Mol. Med. https:\/\/doi.org\/10.1038\/s44321-025-00342-z (2025).","DOI":"10.1038\/s44321-025-00342-z"},{"key":"1008_CR32","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen, T. O. et al. Assessment of Ki67 in Breast Cancer: updated Recommendations From the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst. 113, 808\u2013819 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"1008_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jnci\/djk020","volume":"99","author":"M Dowsett","year":"2007","unstructured":"Dowsett, M. et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl. Cancer Inst. 99, 167\u2013170 (2007).","journal-title":"J. Natl. Cancer Inst."},{"key":"1008_CR34","doi-asserted-by":"publisher","unstructured":"Giltnane, J. M. et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aai7993 (2017).","DOI":"10.1126\/scitranslmed.aai7993"},{"key":"1008_CR35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","volume":"24","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 24, 1029\u20131041 (2023).","journal-title":"Lancet Oncol."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01008-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:08:04Z","timestamp":1794355684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01008-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-01008-w","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC holds stock in Resmed and CSL. ASp has received speaker\u2019s fees from Eli Lilly and is a board member of Breast Cancer Trials, and Melanoma Institute Australia. ASw has received consulting fees from Create Medicines and Phenomic AI, licencing fees from Phenomic AI, research funding from 10X Genomics and Create Medicines, is the board director of Omico, member of the Research Advisory Committee of the National Breast Cancer Foundation (Australia), and member of the Medical Research Advisory Council of the Australian Cancer Research Foundation. BEK has received speaker\u2019s fees from Eli Lilly, Gilead, Astra Zeneca, Eisai, MSD Oncology, is on an advisory board for Daiichi Sankyo\/Astra Zeneca, Gilead, Roche and Novartis, is the chair of the breast cancer group of the Medical Oncology Group of Australia, and chair of the supportive care subgroup of Breast Cancer Trials. She has received travel expenses from Novartis and Pfizer, and compensation for virtual conference attendance from Eli Lilly and MSD Oncology. EKC has received speaker honoraria from Eli Lilly. EL is supported by a fellowship from the National Breast Cancer Foundation, and is on advisory boards\/paid consultant for AstraZeneca, Gilead, Lilly, MSD, Novartis, Pfizer, and Roche, has received royalties from the Walter and Eliza Hall Institute. He is a steering committee member for AstraZeneca, Lilly, Novartis and Roche. He has received institutional research funding from Ellipses, Gilead, Novartis and Pfizer. GJL was supported by NHMRC Fellowships (1175960, 2026004) and the BCRF. He is on the advisory board for Pfizer, has received royalty payments from AbbVie\/Genentech to the Walter and Eliza Hall Institute of Medical Research, and institutional research funding for clinical trials from AbbVie, Pfizer, Beigene. He is a board member of the National Stem Cell Foundation Australia, and member of AACR, ASCO, COSA, MOGA. LH has received prize money from Syndax Pharmaceuticals, research funding from the Garvan Institute of Medical Research, funding from the University of New South Wales, and travel and conference support from Breast Cancer Trials, Pfizer and ESMO. WDT is a scientific advisor for Ellipses Pharma and Havah Therapeutics, and has received research grant funding from Ellipses Pharma. The remaining authors declare they have no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"144"}}